11th Innate Killer Summit

The 11th Innate Killer Summit continues its legacy as the world's leading industry meeting dedicated exclusively to advancing NK and innate immune cell therapies.

This year, the summit unites pioneering biotechs, including NKGen, NKILT, Senti Bio, NKore, and leaders from the MD Anderson Rizvani Lab, alongside translational scientists and platform innovators to showcase breakthrough progress in engineering, manufacturing, persistence, tumor targeting, and clinical translation.

As the NK space becomes increasingly competitive and the path to differentiation narrows, this summit stands firmly alongside the global NK community, providing the clarity, collaboration, and momentum needed to keep innovation moving forward.

With in-depth scientific content, real-world clinical insights across six clinical data updates, and unparalleled access to the full NK ecosystem, the 11th Innate Killer Summit remains the go-to meeting for those shaping the future of innate cell therapy. Now is the moment to align, connect, and act, as breakthroughs accelerate and the field enters a defining year for next-generation NK cell therapies.

URLs:
Website: https://go.evvnt.com/3376597-0?pid=185
Tickets: https://go.evvnt.com/3376597-2?pid=185
Brochure: https://go.evvnt.com/3376597-3?pid=185

Prices:
Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 3697.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2699.00,
Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3047.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2299.00,
Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5397.00,
Service Provider Pricing - 2 Day Pass (Conference Only): USD 3899.00

Speakers: Frank Borriello, Chief Executive Officer, Alloplex Biotherapeutics, Vasil Galat, Chief Executive and Scientific Officer, ARTEC Biotech, Chris Horan, Chief Technical Officer, Artiva Biotherapeutics, Nick Veomett, Vice President, Corporate Development and Program Lead, Artiva Biotherapeutics, Prasad Krishnamurthy, Chief Scientific Officer East, Ocyon Bio, Yi Jin, Chief Executive Officer, GeCell Therapeutics, Adil Duru, Director of Business Development, Glycostem, Monica Raimo, Director of Product and Process Development, Glycostem, Nina Horowitz, Chief Executive Officer, ImmuneBridge, James Liu, Research Scientist, ImmuneBridge, Stefanie Mandl-Cashman, Chief Scientific Officer, Indapta Therapeutics, Hongxia Zhang, Independent Expert, Pinaki Prosad Banerjee, Director and Assistant Professor, Laboratory of Adoptive Cell Therapy Platform, Stem Cell Translational Research, MD Anderson Cancer Center, University of Texas, Henri Bayle, Chief Scientific and Development Officer and Cofounder, NKILT Therapeutics, Tracy Ryan, Founder NKore, Bio Therapeutics, Robert Lewis, Chief Executive Officer and Co-Founder, NOK Therapeutics, Brian Garrison, Vice President of Research, Senti Bio, Kanya Rajangam, President, Chief Medical Officer and Head of Research and Development, Senti Bio, Yansen Xiao, Postdoctoral Researcher, University of Pennsylvania, Neil Sheppard, Director of Research Technologies and Innovation at the Center for Cellular Immunotherapies, University of Pennsylvania

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Date and Time: 23rd March 2026 at 9:00 am to 25th March 2026 at 4:45 pm

Venue details: The Westin San Diego Bayview, 1051 Columbia Street, San Diego, California, 92101, United States